Kukje Pharma Co., Ltd. (002720.KS)
KRW 4970.0
(-2.17%)
KRW 4970.0
(-2.17%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 85.67 Billion KRW | 37.04% |
| 2022 | 62.51 Billion KRW | -12.19% |
| 2021 | 71.19 Billion KRW | -5.23% |
| 2020 | 75.12 Billion KRW | 2.02% |
| 2019 | 73.63 Billion KRW | 27.99% |
| 2018 | 57.53 Billion KRW | -9.91% |
| 2017 | 63.86 Billion KRW | 3.12% |
| 2016 | 61.93 Billion KRW | -9.16% |
| 2015 | 68.18 Billion KRW | 2.29% |
| 2014 | 66.65 Billion KRW | 12.78% |
| 2013 | 59.1 Billion KRW | -0.79% |
| 2012 | 59.57 Billion KRW | -10.85% |
| 2011 | 66.82 Billion KRW | -1.47% |
| 2010 | 67.81 Billion KRW | 9.82% |
| 2009 | 61.75 Billion KRW | 3.34% |
| 2008 | 59.76 Billion KRW | 57.34% |
| 2007 | 37.98 Billion KRW | -5.11% |
| 2006 | 40.02 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 70.7 Billion KRW | -7.05% |
| 2024 Q1 | 76.06 Billion KRW | -11.21% |
| 2023 Q3 | 72.51 Billion KRW | -1.69% |
| 2023 Q4 | 85.67 Billion KRW | 18.14% |
| 2023 Q1 | 64.47 Billion KRW | 3.14% |
| 2023 Q2 | 73.76 Billion KRW | 14.41% |
| 2023 FY | 85.67 Billion KRW | 37.04% |
| 2022 Q1 | 75.25 Billion KRW | 5.71% |
| 2022 FY | 62.51 Billion KRW | -12.19% |
| 2022 Q4 | 62.51 Billion KRW | -10.16% |
| 2022 Q3 | 69.58 Billion KRW | -5.08% |
| 2022 Q2 | 73.31 Billion KRW | -2.59% |
| 2021 Q2 | 74.11 Billion KRW | -1.13% |
| 2021 Q1 | 74.96 Billion KRW | -0.21% |
| 2021 FY | 71.19 Billion KRW | -5.23% |
| 2021 Q4 | 71.19 Billion KRW | -2.61% |
| 2021 Q3 | 73.1 Billion KRW | -1.38% |
| 2020 Q1 | 74.71 Billion KRW | 1.46% |
| 2020 Q3 | 75.79 Billion KRW | -3.57% |
| 2020 Q4 | 75.12 Billion KRW | -0.88% |
| 2020 FY | 75.12 Billion KRW | 2.02% |
| 2020 Q2 | 78.6 Billion KRW | 5.21% |
| 2019 Q4 | 73.63 Billion KRW | 5.71% |
| 2019 FY | 73.63 Billion KRW | 27.99% |
| 2019 Q3 | 69.66 Billion KRW | -9.16% |
| 2019 Q2 | 76.68 Billion KRW | 14.47% |
| 2019 Q1 | 66.99 Billion KRW | 16.43% |
| 2018 Q4 | 57.53 Billion KRW | -1.23% |
| 2018 FY | 57.53 Billion KRW | -9.91% |
| 2018 Q1 | 61.8 Billion KRW | -3.23% |
| 2018 Q2 | 60.64 Billion KRW | -1.88% |
| 2018 Q3 | 58.25 Billion KRW | -3.94% |
| 2017 Q1 | 63.63 Billion KRW | 2.74% |
| 2017 FY | 63.86 Billion KRW | 3.12% |
| 2017 Q4 | 63.86 Billion KRW | -4.97% |
| 2017 Q3 | 67.21 Billion KRW | 7.98% |
| 2017 Q2 | 62.24 Billion KRW | -2.18% |
| 2016 Q3 | 63.44 Billion KRW | -9.87% |
| 2016 Q2 | 70.39 Billion KRW | 2.45% |
| 2016 Q1 | 68.7 Billion KRW | 0.76% |
| 2016 FY | 61.93 Billion KRW | -9.16% |
| 2016 Q4 | 61.93 Billion KRW | -2.38% |
| 2015 Q3 | 69.74 Billion KRW | -1.65% |
| 2015 Q2 | 70.91 Billion KRW | 3.89% |
| 2015 Q1 | 68.25 Billion KRW | 2.4% |
| 2015 FY | 68.18 Billion KRW | 2.29% |
| 2015 Q4 | 68.18 Billion KRW | -2.23% |
| 2014 Q3 | 60.16 Billion KRW | -3.46% |
| 2014 Q1 | 60.32 Billion KRW | 2.07% |
| 2014 Q4 | 66.65 Billion KRW | 10.79% |
| 2014 FY | 66.65 Billion KRW | 12.78% |
| 2014 Q2 | 62.32 Billion KRW | 3.32% |
| 2013 FY | 59.1 Billion KRW | -0.79% |
| 2013 Q2 | 63.91 Billion KRW | 1.09% |
| 2013 Q3 | 60.95 Billion KRW | -4.64% |
| 2013 Q4 | 59.1 Billion KRW | -3.03% |
| 2013 Q1 | 63.22 Billion KRW | 6.13% |
| 2012 Q1 | 67.22 Billion KRW | 0.0% |
| 2012 Q4 | 59.57 Billion KRW | 0.0% |
| 2012 FY | 59.57 Billion KRW | -10.85% |
| 2011 FY | 66.82 Billion KRW | -1.47% |
| 2011 Q1 | 67.81 Billion KRW | -5.35% |
| 2011 Q2 | 64.16 Billion KRW | -5.38% |
| 2011 Q3 | 61.9 Billion KRW | -3.53% |
| 2010 Q4 | 71.65 Billion KRW | -2.8% |
| 2010 FY | 67.81 Billion KRW | 9.82% |
| 2010 Q2 | 71.78 Billion KRW | 16.25% |
| 2010 Q3 | 73.71 Billion KRW | 2.69% |
| 2010 Q1 | 61.75 Billion KRW | -10.56% |
| 2009 FY | 61.75 Billion KRW | 3.34% |
| 2009 Q4 | 69.04 Billion KRW | -2.74% |
| 2009 Q3 | 70.99 Billion KRW | -7.39% |
| 2009 Q2 | 76.66 Billion KRW | 28.29% |
| 2009 Q1 | 59.76 Billion KRW | -5.29% |
| 2008 Q1 | 37.98 Billion KRW | -11.76% |
| 2008 Q2 | 50.85 Billion KRW | 33.9% |
| 2008 Q4 | 63.09 Billion KRW | 11.93% |
| 2008 Q3 | 56.37 Billion KRW | 10.84% |
| 2008 FY | 59.76 Billion KRW | 57.34% |
| 2007 Q2 | 44.67 Billion KRW | 0.0% |
| 2007 Q4 | 43.04 Billion KRW | 3.27% |
| 2007 FY | 37.98 Billion KRW | -5.11% |
| 2007 Q3 | 41.68 Billion KRW | -6.69% |
| 2006 FY | 40.02 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -10.034% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 90.786% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 87.884% |
| HANDOK Inc. | 449.7 Billion KRW | 80.95% |
| Yuhan Corporation | 712.33 Billion KRW | 87.973% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 86.443% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -438.994% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 89.943% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -60.046% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 58.387% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -13.967% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | 42.034% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -21.689% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -10.034% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -135.124% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 65.889% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | 61.183% |
| JW Holdings Corporation | 827.51 Billion KRW | 89.647% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 80.396% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 85.4% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 77.431% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -8.031% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -22.443% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 64.723% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 74.062% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -10.034% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 82.517% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 90.015% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 77.431% |
| Yuhan Corporation | 712.33 Billion KRW | 87.973% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 82.07% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | 37.453% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 83.419% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 77.431% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | 44.563% |
| Korea United Pharm Inc. | 89.96 Billion KRW | 4.774% |
| CKD Bio Corp. | 170.76 Billion KRW | 49.83% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 64.851% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | 45.66% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -99.145% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -8.031% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 86.456% |
| Boryung Corporation | 373.1 Billion KRW | 77.039% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | 58.851% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 58.387% |
| JW Lifescience Corporation | 96.44 Billion KRW | 11.17% |